Acquisitions16 Jun 2026, 04:40 pm
Zydus Lifesciences Completes Assertio Holdings Acquisition
AI Summary
Zydus Lifesciences Ltd. has successfully completed the acquisition of Assertio Holdings, Inc. through its wholly-owned subsidiary, Zara Merger Sub Inc. The cash tender offer, priced at $23.50 per share, saw 66.32% of Assertio's shares tendered. Following the merger, Assertio will become a wholly-owned subsidiary of Zydus, and its shares will be delisted from the Nasdaq Global Market. This strategic move aims to expand Zydus's global healthcare offerings.
Key Highlights
- Zydus Lifesciences acquired Assertio Holdings for $23.50 per share.
- 66.32% of Assertio's shares were tendered in the cash offer.
- Assertio will become a wholly-owned subsidiary of Zydus.
- Assertio's shares will be delisted from Nasdaq.
- The acquisition is expected to enhance Zydus's global market presence.
Price Impact
More from ZYDUSLIFE